Comparative Pharmacology
Head-to-head clinical analysis: CANTIL versus PROPANTHELINE BROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANTIL versus PROPANTHELINE BROMIDE.
CANTIL vs PROPANTHELINE BROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CANTIL (mepenzolate bromide) is a quaternary ammonium anticholinergic agent that blocks muscarinic acetylcholine receptors, reducing gastrointestinal motility and gastric acid secretion.
Antimuscarinic; competitively blocks acetylcholine at postganglionic muscarinic receptors, inhibiting parasympathetic nerve impulses.
50 mg orally three times daily, may increase to 100 mg three times daily if needed
15 mg orally 3 times daily before meals and 30 mg at bedtime; initial dose may be 15 mg 3 times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours; clinically, this supports twice-daily dosing in patients with normal renal function.
Terminal half-life 2.5-4 hours; clinically, dosing every 6 hours maintains therapeutic levels.
Primarily renal excretion of unchanged drug and metabolites; approximately 60-70% eliminated renally, with about 30-40% excreted in feces via biliary elimination.
Approximately 70% renal (tubular secretion) as metabolites and unchanged drug; 30% biliary/fecal.
Category C
Category A/B
Anticholinergic / Antispasmodic
Anticholinergic